

First patient completes landmark Alzheimer's disease trial

- First patient successfully completes XanADu Alzheimer's disease clinical trial
- All 20 XanADu study sites open and actively screening and recruiting patients
- Trial recruitment remains on track, with 26 patients enrolled across the USA, the UK and Australia

Sydney, 7th September 2017: Actinogen Medical (ASX: ACW) is pleased to announce the achievement of another significant milestone with XanADu, its clinical study of Xanamem in Alzheimer's disease. The first patient, who was enrolled into the trial in May 2017, has completed the full 12-week treatment period and the 4-week follow-up phase.

This patient was treated at the Central Coast Neurosciences Research site in New South Wales, Australia, by Professor Jonathan Sturm.

"We are delighted to have successfully completed the very first XanADu trial patient. This patient has completed the full 16 weeks on study, and while we don't as yet know if the patient was taking Xanamem or placebo, we are very pleased with how the trial is progressing. We look forward to enrolling more patients and to the overall study results in 18 months' time," commented Professor Sturm.

This milestone follows the successful initiation of the study earlier this year. All 20 study sites across the USA, the UK and Australia are now open for patient recruitment and 26 patients have been enrolled into XanADu. The study remains on track to enrol the last patient in Q4 2018, and to produce top-line study results in Q1 2019.

"We are very pleased with the progress made with XanADu and the achievement of this significant milestone. With all study sites now open, the trial has achieved the planned patient enrolment momentum that puts us on track to enrol the last patient in just over a year's time. We eagerly look forward to reporting the study results and to hopefully confirming the discovery of a long awaited new treatment for Alzheimer's disease," commented Dr Bill Ketelbey, CEO of Actinogen Medical.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Media Enquires

Caroline Zielinski
Media & Capital Partners
M: +61 400 172 145
E: caroline.zielinski@mcpartners.com.au

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.